Correlation Between Summit Therapeutics and Chemours

Can any of the company-specific risk be diversified away by investing in both Summit Therapeutics and Chemours at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Summit Therapeutics and Chemours into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Summit Therapeutics PLC and Chemours Co, you can compare the effects of market volatilities on Summit Therapeutics and Chemours and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Summit Therapeutics with a short position of Chemours. Check out your portfolio center. Please also check ongoing floating volatility patterns of Summit Therapeutics and Chemours.

Diversification Opportunities for Summit Therapeutics and Chemours

0.25

Correlation Coefficient

Summit Therapeutics  Chemours

Modest diversification

The 3 months correlation between Summit and Chemours is 0.25. Overlapping area represents the amount of risk that can be diversified away by holding Summit Therapeutics PLC and Chemours Co in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Chemours and Summit Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Summit Therapeutics PLC are associated (or correlated) with Chemours. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Chemours has no effect on the direction of Summit Therapeutics i.e., Summit Therapeutics and Chemours go up and down completely randomly.

Pair Corralation between Summit Therapeutics and Chemours

Given the investment horizon of 90 days Summit Therapeutics PLC is expected to generate 1.8 times more return on investment than Chemours. However, Summit Therapeutics is 1.8 times more volatile than Chemours Co. It trades about 0.05 of its potential returns per unit of risk. Chemours Co is currently generating about -0.07 per unit of risk. If you would invest  1,840  in Summit Therapeutics PLC on December 19, 2024 and sell it today you would earn a total of  143.00  from holding Summit Therapeutics PLC or generate 7.77% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Very Weak
Accuracy	100.0%
Values	Daily Returns

Summit Therapeutics PLC  vs.  Chemours Co

Summit Therapeutics PLC

Risk-Adjusted Performance

Insignificant

Compared to the overall equity markets, risk-adjusted returns on investments in Summit Therapeutics PLC are ranked lower than 3 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively unsteady primary indicators, Summit Therapeutics unveiled solid returns over the last few months and may actually be approaching a breakup point.

Chemours

Risk-Adjusted Performance

Very Weak

Over the last 90 days Chemours Co has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of fragile performance in the last few months, the Stock's fundamental indicators remain rather sound which may send shares a bit higher in April 2025. The latest tumult may also be a sign of longer-term up-swing for the firm shareholders.

Pair Trading with Summit Therapeutics and Chemours

The main advantage of trading using opposite Summit Therapeutics and Chemours positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Summit Therapeutics position performs unexpectedly, Chemours can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Chemours will offset losses from the drop in Chemours' long position.

The idea behind Summit Therapeutics PLC and Chemours Co pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.